Previous studies have reported that combination of anti‐ANXA3 (Tong et al, 2018) or Cdk5 inhibition (Ardelt et al, 2019) with sorafenib acts as novel strategies to improve sorafenib response in HCC treatment. The gene discussed is CDK5; the disease is hepatocellular carcinoma.